Stage fright to social success: theatre program shows promise for adults with autism

NCT ID NCT04349644

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a theatre-based program called SENSE Theatre for adults with autism. 72 participants took part in 10 sessions of role-play and peer interaction, ending with a public performance. The goal was to see if this approach could improve social skills like reading faces and having conversations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SENSE Theatre (a peer-mediated, theatre-based behavioral intervention involving role-play and performance)
What this could lead to
If it works, this could offer a fun, practical way to help adults with autism build social confidence and connect better with others.
What could go wrong
This is a small pilot study with only 72 people, so results may not apply to everyone. The program is time-intensive and may not work for all adults with autism.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

72 people

The number who actually took part.

Started

Oct 2020

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

ASD Inclusion Criteria: * diagnosed with ASD based on DSM-V criteria (APA, 2013), by a psychologist, pediatrician or psychiatrist with expertise in ASD will be enrolled. ASD diagnosis will be corroborated by the Autism Diagnostic Observation Schedule (ADOS-2) (Lord, 2012). * Only adults not currently supported by educational opportunities will be enrolled. * Participants must have a full-scale IQ \> or = 70 (WASI; (Wechsler, 2011)) ASD Exclusion Criteria: * Adults with intellectual impairment (WASI; (Wechsler, 2011) score \< 70. * Participants with current, frequent and uncontrolled aggression toward other persons or property in the past 6 months will be excluded based on phone screening and questions from the Adult Behavior Checklist (Achenbach, 2001) (e.g., "Physically attacks people"). * Participants with evidence of suicidality based on care-provider report, self-report, or clinical interview (i.e., endorsement of suicidal ideation in the past month and/or suicidal behavior in the past three months on the Columbia Suicide Severity Rating Scale (Posner, 2011), * Previous SENSE Theatre® participants will be excluded. Care-giver Inclusion Criteria: * must be at least 18 years of age * must be a parent, close relative, or spouse of the adult participant with ASD. * must be able to provide current and historical observations of the functioning of the participant with ASD. * must live in close proximity to and have frequent contact with the participant with ASD. Care-giver Exclusion Criteria: \- Anyone not meeting inclusion criteria. Confederates Inclusion Criteria: * must be at least 18 years of age * typically developing individual with no neurodevelopmental disorder. * must successfully complete training and demonstrate consistent administration of research protocols. Confederate Exclusion Criteria: \- Anyone not meeting inclusion criteria. Peers Inclusion Criteria: * must be at least 18 years of age * typically developing individual with no neurodevelopmental disorder. * must have an expressed interest in supporting young adults and adults with developmental disabilities or ASD * must successfully complete SENSE Theatre® training. Peers Exclusion Criteria: \- Anyone not meeting inclusion criteria.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autism spectrum disorder are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.